Abstract
Colorectal cancer is a leading cause of cancer death throughout the world. The high prevalence and mortality associated with colon cancer make effective prevention and treatment an important public health and economic concern. Among the few agents known to inhibit colorectal tumorigenesis are the nonsteroidal antiinflammatory drugs or NSAIDs, as well as newer agents such as celecoxib and rofecoxib. Both epidemiologic studies and investigations with animals show that these compounds possess marked anti-colorectal cancer properties. NSAIDS are widely known to be inhibitors of the cyclooxygenase (COX) enzymes, and it is thought that the chemopreventive effects of NSAIDs are at least in part due to this ability to inhibit COX. More recent studies, however, have suggested that NSAIDs may also exert anti-cancer effects through mechanisms independent of COX inhibition. COX-dependent and COX-independent mechanisms are not mutually exclusive and it is likely that both are involved in the biological activity of NSAIDs.
Keywords: cyclooxygenase, colon, cancer, chemoprevention, apoptosis, arachidonic acid, nonsteroidal anti-inflammatory drug
Current Cancer Drug Targets
Title: Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention
Volume: 3 Issue: 6
Author(s): Timothy A. Chan
Affiliation:
Keywords: cyclooxygenase, colon, cancer, chemoprevention, apoptosis, arachidonic acid, nonsteroidal anti-inflammatory drug
Abstract: Colorectal cancer is a leading cause of cancer death throughout the world. The high prevalence and mortality associated with colon cancer make effective prevention and treatment an important public health and economic concern. Among the few agents known to inhibit colorectal tumorigenesis are the nonsteroidal antiinflammatory drugs or NSAIDs, as well as newer agents such as celecoxib and rofecoxib. Both epidemiologic studies and investigations with animals show that these compounds possess marked anti-colorectal cancer properties. NSAIDS are widely known to be inhibitors of the cyclooxygenase (COX) enzymes, and it is thought that the chemopreventive effects of NSAIDs are at least in part due to this ability to inhibit COX. More recent studies, however, have suggested that NSAIDs may also exert anti-cancer effects through mechanisms independent of COX inhibition. COX-dependent and COX-independent mechanisms are not mutually exclusive and it is likely that both are involved in the biological activity of NSAIDs.
Export Options
About this article
Cite this article as:
Chan A. Timothy, Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481723
DOI https://dx.doi.org/10.2174/1568009033481723 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Current Pharmaceutical Design Socio-economic Aspects of Alzheimer's Disease
Current Alzheimer Research Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Withdrawal Notice: Application of Nanomaterials in Development of Electrochemical Sensors and Drug Delivery Systems for Anticancer Drugs
Current Drug Delivery Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Myc - What We have Learned from Flies
Current Drug Targets CpG Island Methylation in Precursors of Gastrointestinal Malignancies
Current Molecular Medicine Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Anti-Cancer Agents in Medicinal Chemistry Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine Concentration-Dependent Bimodal Effect of Specific 18 kDa Translocator Protein (TSPO) Ligands on Cell Death Processes Induced by Ammonium Chloride: Potential Implications for Neuropathological Effects Due to Hyperammonemia
CNS & Neurological Disorders - Drug Targets Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets